The UK's Competition and Markets Authority (CMA) has now formally concluded that three pharmaceutical companies - Aspen, Tiofarma, and Amilco - took part in an illegal arrangement that inflated the price of life-saving medicine fludrocortisone.
A pharmaceutical company director is now banned from holding a director role at any UK company for the next five years after making illegal arrangements.